sisarv, Author at Abidipharma

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

In Uncategorized

Posted July 24, 2018

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

READ MORE

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

In Uncategorized

Posted July 24, 2018

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

READ MORE

Research article Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

In Uncategorized

Posted July 24, 2018

Research article Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

READ MORE

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

In Uncategorized

Posted July 24, 2018

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

READ MORE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

In Uncategorized

Posted July 24, 2018

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

READ MORE

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

In Uncategorized

Posted July 24, 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

READ MORE

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

In Uncategorized

Posted July 24, 2018

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

READ MORE

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

In Uncategorized

Posted July 24, 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

READ MORE

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

In Uncategorized

Posted July 24, 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

READ MORE

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

In Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet, Ziptin - Zipmet

Posted July 24, 2018

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

READ MORE